Ridgeback Capital Investments L.P. Acquires Shares of 359,231 Pyxis Oncology, Inc. (NASDAQ:PYXS)

Ridgeback Capital Investments L.P. acquired a new position in Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 359,231 shares of the company's stock, valued at approximately $560,000. Pyxis Oncology accounts for 100.0% of Ridgeback Capital Investments L.P.'s holdings, making the stock its biggest position. Ridgeback Capital Investments L.P. owned approximately 0.60% of Pyxis Oncology at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. ProShare Advisors LLC bought a new stake in Pyxis Oncology during the fourth quarter worth approximately $26,000. Ameriprise Financial Inc. acquired a new stake in Pyxis Oncology in the fourth quarter worth about $35,000. Caption Management LLC purchased a new stake in Pyxis Oncology in the fourth quarter valued at approximately $35,000. Commonwealth Equity Services LLC lifted its holdings in shares of Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock valued at $41,000 after buying an additional 10,000 shares during the period. Finally, Graham Capital Management L.P. purchased a new position in shares of Pyxis Oncology during the 4th quarter valued at approximately $47,000. Institutional investors own 39.09% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PYXS shares. HC Wainwright reiterated a "buy" rating and issued a $5.00 target price on shares of Pyxis Oncology in a report on Monday. Royal Bank of Canada restated an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $9.00.

Pyxis Oncology Stock Performance

NASDAQ:PYXS traded down $0.02 on Tuesday, hitting $1.22. 133,089 shares of the stock were exchanged, compared to its average volume of 569,213. The company's 50-day moving average price is $1.05 and its 200 day moving average price is $1.60. The stock has a market capitalization of $75.27 million, a price-to-earnings ratio of -1.18 and a beta of 1.15. Pyxis Oncology, Inc. has a 52 week low of $0.83 and a 52 week high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, equities research analysts predict that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.